ONE Bio Corp (ONBI) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of ONE Bio Corp $0.00, price $0.00, upside +0.0%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ONE Bio Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.0001 – $0.1500 · fair‑value band $0.0005 – $0.0005 · the $0.0005 price screens below the $0.0005 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow ONE Bio in your weekly email
Every Wednesday you see whether ONE Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP).
Show more
ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE business unit engages in the development, manufacture, and commercialization of bio-ecological products and over-the-counter products utilizing the extractions of tobacco leaves and various other plant materials. It produces chemical and herbal extracts for use in a range of health and wellness products, including chemical extracts comprising Solanesol and Coenzyme Q10; and herabal extracts, such as Resveratrol, 5-Hydroxytryptophan, Ganoderma Tea, and powdered and particulate fertilizers. This business unit distributes its products through independent third party distributors, universities, and hospital research centers to the bio-health industry and raw chemical intermediates industry in the People's Republic of China. The OP business unit manufactures various consumer and commercial use health and energy drinks, organic food products, and fertilizers primarily based on bamboo in the People's Republic of China. Its products include boiled bamboo shoot cans, boiled bamboo shoot cans with vacuum packing, boiled mixed vegetables, and boiled seasoned vegetables, as well as Kamameshi, a Japanese rice dish. This segment distributes its products directly to supermarket chains, hotels, hospitals, and restaurants, as well as through a network of independent third party distributors. ONE Bio Corp. exports its products to Japan, southeast Asia, Europe, and North America. The company was formerly known as ONE Holdings, Corp. and changed its name to ONE Bio Corp. in November 2009. ONE Bio Corp. was incorporated in 2000 and is headquartered in Aventura, Florida.
Stock analysis
ONE Bio Corp (ONBI) currently trades at $0.0005, while our model-based Fair Value estimate is $0.0005, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $0.0012 per share, and 11 of the 24 models we run sit above the $0.0005 price.
Bear case: the Asset-Based group reads lowest at $0.0001, and 13 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0005 (bear) to $0.0005 (bull), the price of $0.0005 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
ONE Bio Corp reported revenue of $52.3M in FY2010 versus $208K in FY2006, a compound +298.4%/yr. Reported net income was $8.7M in FY2010.
Key figures
Market cap $10.0K · P/E ratio 0.1 · EPS (TTM) $0.0100 · Net margin 16.6% · Return on equity 20.1% · Return on assets (EBIT) −4.3% · Operating margin 28.2% · Revenue (TTM) $53.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 150% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 0%, ONBI screens richer than that median.
Fair Value models
Bear $0.0005Fair Value $0.0005Bull $0.0005
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+136.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+348.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+216.8%
’05
’06
’07
’09
’10
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+37.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+37.9%
Dividend (yield on the price)0.0%
Profit margin 2005 to 2010 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−31% → 26%
2010 sits 187% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 584 stocks
Beats the industry median on 9/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Above median
Fair Value upside+0.0% · Top 25%
Profitability
Return on equity (TTM)20.1% · Top 25%
Return on assets12.5% · Top 25%
Net margin (TTM)16.6% · Above median
Operating margin (TTM)28.2% · Top 25%
Growth and dividend
Revenue growth0.3% · Above median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ONE Bio Corp Fair Value". https://www.fairvalue-calculator.com/stock/ONBI
Frequently asked questions
Is ONE Bio Corp (ONBI) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0005 versus the last price from Sep 25, 2026 of $0.0005, about +0% upside (fairly valued).
What is the fair value of ONBI?
Our model-based fair value for ONE Bio Corp is $0.0005 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0005.
What is the quality score of ONBI?
ONE Bio Corp has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ONE Bio Corp (ONBI)?
Our model-based price target is the fair value of $0.0005 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario $0.0005, optimistic scenario $0.0005. It is a calculation from audited fundamentals, not an analyst target.
What is the ONE Bio Corp stock forecast for 2026?
Our models put fair value at $0.0005, about +0% upside versus the last price from Sep 25, 2026 of $0.0005 (fairly valued). Cautious scenario $0.0005, optimistic scenario $0.0005. The calculation is refreshed regularly with new filings.
What is the revenue of ONE Bio Corp (ONBI)?
ONE Bio Corp reported trailing-twelve-month revenue of about $53.9M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of ONE Bio Corp (ONBI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ONE Bio Corp it is $0.0005 per share (as of Sep 27, 2026), against a price of $0.0005. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is ONE Bio Corp stock overvalued or undervalued in 2026?
As of Sep 27, 2026, ONBI trades below its calculated fair value: price $0.0005, fair value $0.0005, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONBI?
No. The price is what the market pays today ($0.0005); the fair value is what the company's own numbers justify ($0.0005). For ONE Bio Corp the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is ONE Bio Corp worth?
The market values ONE Bio Corp at about $10.0K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0005; our models calculate a fair value of $0.0005 per share.
What do the bullish and bearish scenarios say about ONBI?
Our models span a range for ONE Bio Corp: cautious scenario $0.0005, base $0.0005, optimistic $0.0005 per share (as of Sep 27, 2026, price $0.0005). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ONBI?
ONE Bio Corp trades at a price-to-earnings ratio of 0.1 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.0005 is built from several models across several years.
How solid is the balance sheet of ONE Bio Corp (ONBI)?
Balance-sheet figures for ONE Bio Corp (as of Sep 27, 2026): return on equity 20.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is ONBI from its 52-week high?
ONE Bio Corp trades at $0.0005, at its 52-week high of $0.0005 and 150% above the low of $0.0002 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0005 is for.
Which stocks are comparable to ONE Bio Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ONE Bio Corp stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0005, calculated fair value $0.0005 (+0%), Quality Score 47/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONBI calculated?
We run ONE Bio Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0005, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. ONE Bio Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ONE Bio Corp (ONBI)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0005. Our model-based fair value is $0.0005, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ONE Bio Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0005 to $0.0005), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of ONE Bio Corp
How large is the market capitalisation of ONE Bio Corp (ONBI)?
The market capitalisation of ONE Bio Corp is $10.0K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ONE Bio Corp (ONBI)?
Earnings per share at ONE Bio Corp are $0.0100 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ONE Bio Corp (ONBI)?
The net margin of ONE Bio Corp is 16.6% (fiscal year 2010). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ONE Bio Corp (ONBI)?
The return on equity (ROE) of ONE Bio Corp is 20.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ONE Bio Corp (ONBI)?
On an EBIT basis the return on assets of ONE Bio Corp is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ONE Bio Corp (ONBI)?
The operating margin of ONE Bio Corp is 28.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ONE Bio Corp (ONBI)?
Revenue at ONE Bio Corp is growing +0.3% versus a year earlier (3y avg +349%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ONE Bio Corp (ONBI)?
Earnings per share at ONE Bio Corp are growing −24.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ONE Bio Corp (ONBI) generate?
The free cash flow of ONE Bio Corp is $4.6M (fiscal year 2010). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ONE Bio Corp (ONBI) carry?
The net debt of ONE Bio Corp is $9.0M (fiscal year 2010, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ONE Bio Corp in the live analysis
One click puts ONE Bio Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026